Lv1
20 积分 2026-07-28 加入
Complement activation and effector pathways in membranous nephropathy
18小时前
已完结
Membranous nephropathy: new pathogenic mechanisms and their clinical implications
18小时前
已完结
Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis
7天前
已完结
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
8天前
已完结
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
8天前
已完结
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
8天前
已完结
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
9天前
已完结
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study
9天前
已完结
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
9天前
已完结
Miscreant myeloproliferative disorder stem cells
9天前
已完结
皖公网安备34019202002308
